Invivyd, Inc.
7.30%
20,262,170
1832038
00534A102
Dec 22, 2025
Dec 29, 2025, 04:15 PM
Reporting Persons (1)
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| Adimab, LLC | Other | 7.30% | 20,262,170 | 20,262,170 | 0 |
Disclosure Items (2)
Common Stock, $0.0001 par value per share
Invivyd, Inc.
209 Church Street, New Haven, CT, 06510
Item 5 of the Schedule 13D is hereby amended and restated as follows: (a) Amount beneficially owned: 20,262,170; Percent of Class: 7.3%. The above percentage is based on 277,122,834 shares of Common Stock outstanding, which includes 233,122,834 shares of Common Stock outstanding as of October 30, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 and 44,000,000 shares of Common Stock issued on November 19, 2025, as reported in the Issuer's Current Report on Form 8-K filed on November 19, 2025.
(b) The Reporting Person has sole voting and sole dispositive power with respect to all of the shares of Common Stock that it beneficially owns.
On December 23, 2025, the Reporting Person sold 192,320 shares of Common Stock at a weighted average price of $3.0028 per share in a series of open market transactions. These shares were sold in multiple transactions at prices ranging from $3.00 to $3.005 per share. The Reporting Person undertakes to provide to the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within this range.
None
Not applicable